Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.
Author: COVIDRIVE consortium
Launch of an ambitious cross-pharma study by the public-private partnership ‘COVIDRIVE’: a multi-country European study to continuously monitor COVID-19 vaccine effectiveness against severe disease
17/09/2021- COVIDRIVE, a long-term, multi-country, hospital-based study investigating the effectiveness of COVID-19 vaccines across Europe has recently begun with the successful recruitment of its first patient – at a site in Valencia (Spain).
COVIDRIVE consists of a unique, cross-pharma consortium of vaccine companies and research groups who are joining forces to collect real-world data on the effectiveness of COVID-19 vaccines. This first COVIDRIVE study will monitor for variants of concern and help provide answers to the critical questions relating to COVID-19 vaccine effectiveness, including duration of protection of the different vaccines, impact of additional vaccine doses and different vaccine combinations.
New public-private partnership COVIDRIVE to assess brand-specific COVID-19 vaccine effectiveness in Europe
19/07/2021 – A new public-private partnership – COVIDRIVE – announced today that it will begin studies to assess the effectiveness of multiple COVID-19 vaccines in Europe to support the region’s public health response and to address the vaccine companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small medium enterprises and vaccine companies, including FISABIO (Spain), P95 (Belgium), THL (Finland), AstraZeneca (UK), CureVac (Germany), Janssen (Belgium), Sanofi-Pasteur (France) and GSK (Belgium).
